HC Wainwright Reaffirms “Buy” Rating for Kiora Pharmaceuticals (NASDAQ:KPRX)

HC Wainwright restated their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a report released on Monday morning, Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q2 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at $0.15 EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ:KPRX opened at $0.53 on Monday. The firm has a 50 day moving average of $0.56 and a 200-day moving average of $0.58. Kiora Pharmaceuticals has a 12 month low of $0.45 and a 12 month high of $2.24.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals comprises about 1.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 22nd biggest position. Rosalind Advisors Inc. owned approximately 8.76% of Kiora Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.